65,437 trials
Fatigue
Primary: Histologic Thermal Injury to Umbilical Port Site Skin — 24; 13 participants
Breast Cancer
Primary: The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue…
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5380; 4520; 2280 nmol*h/L
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Glycemic Control as Measured by HbA1c (4 mm vs. 8 mm) — 7.59; 7.46; 7.63; 7.59 HbA1c (%)
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.022; 0.150; 0.152; 0.136 Liter — p=<0.0001
Transplant Rejection
Primary: Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population…
Myopia
Primary: Participant's Subjective Rating of Comfort (Questionnaire) — 92; 91; 96; 93 units on a scale
Intradialytic Hypotension
Primary: Change in Average Mean Arterial Blood Pressure During Hemodialysis — -0.12; 1.95; 1.60 mmHg — p=0.693
Unstable Angina · Myocardial Infarction
Primary: Composite of Death, Myocardial (re-) Infarction, or Stroke — 153; 163 participants — p=0.15
Multiple Sclerosis
Primary: Fain-Tolosa-Marin Tremor Rating Scale (TRS) Change Score for Both VIM and VO ON (Baseline Minus 6 Months Post-implant) — -17.6 units on a scale — p=.026
Depression
Primary: Number of IL-2 Treatments Tolerated — 18.4; 19.8 IL-2 treatments
Postpartum Hemorrhage
Primary: Intraoperative Blood Loss — 357.8; 641.7; 457.5 millilitres
Vestibular Diseases · Labyrinth Diseases · Ear Diseases
Primary: Assessment of the Efficacy of the SEMD Device in Improving Vestibular Function Was Evaluated With Change in Pre Test to Post Test 1 Sensory Organization Test (SOT)…
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Colorectal Cancer
Primary: Objective Response Rate — 0.33; 0.38; 0.49 proportion